News for AtriCure, Inc. (ATRC)

On May 28, 2025, Vinayak Doraiswamy, the Chief Scientific Officer at AtriCure Inc, sold 2,500 shares of the company, according to a SEC Filing. Following this t

Summary AtriCure Inc (ATRC), a prominent innovator in surgical treatments for atrial fibrillation (Afib) and related conditions, announced its participation in

**media[626103]**

UBS has revised its price target for AtriCure (ATRC), decreasing it from $60 to $58, while maintaining a Buy rating on the stock. The decision reflects the robu

BTIG has adjusted its price target for AtriCure (ATRC), reducing it from $58 to $52, while maintaining a Buy rating on the stock. The company's first-quarter pe

Canaccord analyst William Plovanic has revised the price target for AtriCure (ATRC), reducing it to $51 from the previous $52. Despite this adjustment, the anal

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please ...

Total Revenue: $124 million, 14% growth year-over-year.Adjusted EBITDA: $9 million, over 200% improvement from Q1 2024.Appendage Management Revenue Growth: 19%

Apr 29, 2025 / 08:30PM GMTOperator Good afternoon and welcome to AtriCure's First Quarter 2025 Earnings Conference Call. This call is being recorded for replay

AtriCure, Inc. (NASDAQ:ATRC) Q1 2025 Earnings Conference Call April 29, 2025 4:30 PM ETCompany ParticipantsMarissa Bych - Investor Relations, Gilmartin...

[url="]AtriCure, Inc.[/url] [url="](Nasdaq: ATRC)[/url], a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial a

AtriCure (ATRC) has set its revenue expectations for the full year 2025 between $517 million and $527 million. The company's management has also estimated the A

The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Summary AtriCure Inc (ATRC), a leader in surgical treatments for atrial fibrillation and related conditions, announced the first use of its latest innovation, t

AtriCure stock has had a recent drop of roughly 25% even as the company delivered revenue growth in the mid-teens in FY 2024. Click to read why ATRC is a Hold.

On March 5, 2025, Karen Prange, a Director at AtriCure Inc (ATRC), sold 6,100 shares of the company. Following this transaction, the insider now owns 17,828 sha

Transaction Overview On December 31, 2024, First Light Asset Management, LLC (Trades, Portfolio) executed a significant reduction in its holdings of KORU Medica

On December 31, 2024, Hood River Capital Management LLC (Trades, Portfolio) made a strategic move by increasing its stake in AtriCure Inc (ATRC). The firm added

AtriCure (ATRC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).